239 related articles for article (PubMed ID: 11511317)
1. Ultraviolet exposure as the main initiator of p53 mutations in basal cell carcinomas from psoralen and ultraviolet A-treated patients with psoriasis.
Seidl H; Kreimer-Erlacher H; Bäck B; Soyer HP; Höfler G; Kerl H; Wolf P
J Invest Dermatol; 2001 Aug; 117(2):365-70. PubMed ID: 11511317
[TBL] [Abstract][Full Text] [Related]
2. High frequency of ultraviolet mutations at the INK4a-ARF locus in squamous cell carcinomas from psoralen-plus-ultraviolet-A-treated psoriasis patients.
Kreimer-Erlacher H; Seidl H; Bäck B; Cerroni L; Kerl H; Wolf P
J Invest Dermatol; 2003 Apr; 120(4):676-82. PubMed ID: 12648234
[TBL] [Abstract][Full Text] [Related]
3. The ultraviolet fingerprint dominates the mutational spectrum of the p53 and Ha-ras genes in psoralen + ultraviolet A keratoses from psoriasis patients.
Wolf P; Kreimer-Erlacher H; Seidl H; Bäck B; Soyer HP; Kerl H
J Invest Dermatol; 2004 Jan; 122(1):190-200. PubMed ID: 14962108
[TBL] [Abstract][Full Text] [Related]
4. Incidence and risk factors associated with a second squamous cell carcinoma or basal cell carcinoma in psoralen + ultraviolet a light-treated psoriasis patients.
Katz KA; Marcil I; Stern RS
J Invest Dermatol; 2002 Jun; 118(6):1038-43. PubMed ID: 12060400
[TBL] [Abstract][Full Text] [Related]
5. High mutation frequency at Ha-ras exons 1-4 in squamous cell carcinomas from PUVA-treated psoriasis patients.
Kreimer-Erlacher H; Seidl H; Bäck B; Kerl H; Wolf P
Photochem Photobiol; 2001 Aug; 74(2):323-30. PubMed ID: 11547572
[TBL] [Abstract][Full Text] [Related]
6. Psoralen photochemotherapy, clinical efficacy, and photomutagenicity: the role of molecular epidemiology in minimizing risks.
Gasparro FP; Liao B; Foley PJ; Wang XM; McNiff JM
Environ Mol Mutagen; 1998; 31(2):105-12. PubMed ID: 9544188
[TBL] [Abstract][Full Text] [Related]
7. High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients.
Lim JL; Stern RS
J Invest Dermatol; 2005 Mar; 124(3):505-13. PubMed ID: 15737190
[TBL] [Abstract][Full Text] [Related]
8. An unexpected spectrum of p53 mutations from squamous cell carcinomas in psoriasis patients treated with PUVA.
Wang XM; McNiff JM; Klump V; Asgari M; Gasparro FP
Photochem Photobiol; 1997 Aug; 66(2):294-9. PubMed ID: 9277151
[TBL] [Abstract][Full Text] [Related]
9. p53 mutation in nonmelanoma skin cancers occurring in psoralen ultraviolet a-treated patients: evidence for heterogeneity and field cancerization.
Stern RS; Bolshakov S; Nataraj AJ; Ananthaswamy HN
J Invest Dermatol; 2002 Aug; 119(2):522-6. PubMed ID: 12190879
[TBL] [Abstract][Full Text] [Related]
10. p53 mutation in squamous cell carcinomas from psoriasis patients treated with psoralen + UVA (PUVA).
Nataraj AJ; Wolf P; Cerroni L; Ananthaswamy HN
J Invest Dermatol; 1997 Aug; 109(2):238-43. PubMed ID: 9242514
[TBL] [Abstract][Full Text] [Related]
11. Infrequent p53 mutations in arsenic-related skin lesions.
Castrén K; Ranki A; Welsh JA; Vähäkangas KH
Oncol Res; 1998; 10(9):475-82. PubMed ID: 10223623
[TBL] [Abstract][Full Text] [Related]
12. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study.
Stern RS; Liebman EJ; Väkevä L
J Natl Cancer Inst; 1998 Sep; 90(17):1278-84. PubMed ID: 9731734
[TBL] [Abstract][Full Text] [Related]
13. Nonmonoclonal PTCH gene mutations in psoralen plus UVA-associated basal cell carcinomas.
Heitzer E; Wolf P
J Invest Dermatol; 2008 Mar; 128(3):746-9. PubMed ID: 18059486
[No Abstract] [Full Text] [Related]
14. The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis.
Stern RS; Bagheri S; Nichols K;
J Am Acad Dermatol; 2002 Jul; 47(1):33-9. PubMed ID: 12077578
[TBL] [Abstract][Full Text] [Related]
15. Biological consequences of 8-methoxypsoralen-photoinduced lesions: sequence-specificity of mutations and preponderance of T to C and T to a mutations.
Besaratinia A; Pfeifer GP
J Invest Dermatol; 2004 Dec; 123(6):1140-6. PubMed ID: 15610526
[TBL] [Abstract][Full Text] [Related]
16. The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study.
Nijsten TE; Stern RS
J Invest Dermatol; 2003 Aug; 121(2):252-8. PubMed ID: 12880415
[TBL] [Abstract][Full Text] [Related]
17. Signature p53 mutation at DNA cross-linking sites in 8-methoxypsoralen and ultraviolet A (PUVA)-induced murine skin cancers.
Nataraj AJ; Black HS; Ananthaswamy HN
Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7961-5. PubMed ID: 8755585
[TBL] [Abstract][Full Text] [Related]
18. p53 mutations in basal cell carcinomas arising in routine users of sunscreens.
Rosenstein BS; Phelps RG; Weinstock MA; Bernstein JL; Gordon ML; Rudikoff D; Kantor I; Shelton R; Lebwohl MG
Photochem Photobiol; 1999 Nov; 70(5):798-806. PubMed ID: 10568172
[TBL] [Abstract][Full Text] [Related]
19. Carcinogen-specific mutation pattern in the p53 tumour suppressor gene in UV radiation-induced basal cell carcinoma.
Weihrauch M; Bader M; Lehnert G; Wittekind C; Tannapfel A; Wrbitzky R
Int Arch Occup Environ Health; 2002 Apr; 75(4):272-6. PubMed ID: 11981662
[TBL] [Abstract][Full Text] [Related]
20. The role of PUVA in the treatment of psoriasis. Photobiology issues related to skin cancer incidence.
Gasparro FP
Am J Clin Dermatol; 2000; 1(6):337-48. PubMed ID: 11702610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
